Fox Run Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Fox Run Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-15,010	Closed	-$358K	–	434
2019 Q4	$358K	Buy	+15,010	New	+$414K	0.29%	124
2019 Q3	–	Sell	-8,124	Closed	-$220K	–	643
2019 Q2	$220K	Buy	+8,124	New	+$255K	0.15%	339
2018 Q4	–	Sell	-12,308	Closed	-$328K	–	831
2018 Q3	$328K	Sell	12,308 -16,054	-57%	-$524K	0.14%	320
2018 Q2	$1.07M	Buy	+28,362	New	+$1.08M	0.34%	22
2017 Q4	–	Sell	-9,700	Closed	-$524K	–	974
2017 Q3	$524K	Buy	+9,700	New	+$569K	0.15%	278
2016 Q3	–	Sell	-21,000	Closed	-$496K	–	768
2016 Q2	$496K	Sell	21,000 -5,800	-22%	-$143K	0.24%	131
2016 Q1	$547K	Buy	+26,800	New	+$850K	0.37%	61

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Fox Run Management's PTLA Position: Q1 2020 in Review

Fox Run Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 15,010 shares — an estimated $358K sold.

Fox Run Management first reported a position in PTLA in Q1 2016 and held it in 7 quarters. The position peaked at $1.07M in Q2 2018. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

Fox Run Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Fox Run Management sold 15,010 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $358K.
Fox Run Management first reported a position in Portola Pharmaceuticals, Inc. in Q1 2016 and held it in 7 quarters.
Fox Run Management's Portola Pharmaceuticals, Inc. position peaked at $1.07M in Q2 2018.
187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on Fox Run Management's 13F filing for Q1 2020, filed 8 May 2020.